Aerie Pharmaceuticals (NASDAQ: AERI) announces an inducement grant to CEO Raj Kannan, appointed in December 2021. Kannan will receive inducement equity awards worth $5.5 million, split into two parts. The first awards, valued at $3.5 million, consist of 387,169 stock options and 215,783 restricted shares with a four-year vesting schedule. The second set, worth $2.0 million, is tied to an annual grant in February 2022. These awards were approved by independent directors outside of the stockholder-approved equity plan, complying with Nasdaq Listing Rule 5635(c)(4).
Aerie Pharmaceuticals (NASDAQ:AERI) has announced the appointment of Raj Kannan as Chief Executive Officer and director effective December 20, 2021. Kannan has over 25 years of experience in building successful organizations, launching products, and providing strategic direction, notably as CEO at Chiasma. Aerie’s Board expressed confidence in his ability to lead the company towards becoming a premier ophthalmology firm, leveraging its strong glaucoma portfolio and two Phase 3-ready programs.
Aerie Pharmaceuticals (NASDAQ: AERI) has entered an exclusive development and commercialization agreement with Santen for Rhopressa® and Rocklatan® in Europe, CIS countries, China, India, Latin America, and Oceania. Aerie will receive an upfront payment of $88 million and could earn up to $77 million in milestones, alongside royalties on net sales. This collaboration expands upon their existing partnership in Japan and aims to enhance global access to these glaucoma treatments. Aerie's manufacturing of these products will occur at its facility in Ireland, potentially reducing costs.
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a company focused on innovative therapies for glaucoma and retinal diseases, announced that Interim Executive Chairman Benjamin McGraw, III, Pharm.D. will participate in three upcoming virtual investor conferences. These include the Stifel 2021 Virtual Healthcare Conference on November 16, Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, and Ophthalmology Day at BTIG on November 30. Live presentations and replays will be accessible on Aerie’s website.
Aerie Pharmaceuticals (NASDAQ:AERI) reported a 46% increase in net revenues for Q3 2021, totaling $29.3 million, compared to the prior year. The net revenue per bottle rose by 16% to $89, aided by renegotiated wholesaler fees. The company ended the quarter with $168 million in cash and investments, reducing net cash used in operations to $19 million. Aerie expects to initiate Phase 3 studies for its pipeline candidates AR-15512 and AR-1105 in early 2022, following positive Phase 2 results and discussions with regulatory agencies.
Aerie Pharmaceuticals (NASDAQ: AERI) is set to release its third quarter 2021 financial results after market close on November 4, 2021. Following the release, a live conference call and webcast will take place at 5:00 p.m. Eastern Time to discuss these results and provide a general business update. Investors can access the webcast via the company's website or by calling in. Aerie focuses on developing therapies for open-angle glaucoma and ocular surface diseases, with products like Rhopressa and Rocklatan already on the market since 2018 and 2019, respectively.
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) presented an overview of its glaucoma franchise at the Ophthalmology Innovation Summit. The presentation highlighted growth in the U.S. and advancements towards market entry in Europe and Japan. Aerie focuses on developing therapies for open-angle glaucoma and ocular surface diseases. Its products include Rhopressa® and Rocklatan®, both aimed at reducing elevated intraocular pressure. Additionally, Aerie is expanding its portfolio with new candidates targeting other ophthalmic conditions.
Aerie Pharmaceuticals (NASDAQ:AERI) reported positive topline results from its Phase 3 clinical trial in Japan for netarsudil ophthalmic solution 0.02%. The study demonstrated that netarsudil 0.02% once daily significantly lowered intraocular pressure (IOP) compared to ripasudil 0.4% twice daily, achieving a reduction of 4.7 mmHg (22.6%) versus 3.0 mmHg (14.3%) at four weeks (p0.0001). With these results, Aerie aims to capitalize on the unmet need in the Japanese market, where ripasudil is the only available Rho kinase inhibitor, potentially enhancing its product's commercial prospects.
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) recently showcased its retina product candidates at the Ophthalmology Innovation Summit. The presentation highlighted the company's proprietary PRINT® drug delivery platform and three key candidates: AR-1105 (Phase 3 ready), AR-13503 (Phase 2a), and AR-14034 (preclinical). Aerie, focused on developing ophthalmic therapies, already markets Rhopressa® and Rocklatan®, aimed at treating elevated intraocular pressure. The presentation reinforces Aerie's commitment to innovation in ophthalmology and its growth strategy.
Aerie Pharmaceuticals (NASDAQ: AERI) announced the presentation of topline results from its Phase 2 clinical trial of AR-1105, a dexamethasone intravitreal implant, for treating macular edema due to retinal vein occlusion. The results will be presented at the 39th Annual Scientific Meeting of the American Society of Retina Specialists on October 12, 2021, in San Antonio, Texas. Aerie is focused on developing innovative therapies for ocular conditions, having launched its first two products, Rhopressa and Rocklatan, in 2018 and 2019, respectively.